Mounjaro Side Effects — What Happens to Your Liver

The most common side effects of Mounjaro are gastrointestinal — nausea, vomiting, diarrhoea, and constipation. These follow the same profile as semaglutide (Ozempic/Wegovy) but may be more intense at equivalent weight loss stages, reflecting Mounjaro's greater potency and the more rapid rate of weight reduction it produces.

Across the SURMOUNT trial program, gastrointestinal events were the most frequent adverse effects and the primary reason for treatment discontinuation during dose escalation. Most symptoms were mild to moderate and resolved as patients reached maintenance dose.

Slow dose escalation — following the standard Mounjaro schedule — is the most effective strategy for managing early GI side effects. These symptoms are not liver-related.

No clinically significant hepatotoxicity has been identified in the SURMOUNT trial program involving thousands of patients over 72–84 weeks. Liver enzyme trends in patients with metabolically driven elevations consistently improved alongside weight loss.

Phase 2 dedicated liver disease trial data shows tirzepatide produces significant reductions in liver fat content and liver enzyme levels — with over 62% of participants with serious liver inflammation seeing it resolve after 52 weeks.

The NIH LiverTox database entry for tirzepatide (June 2025) classifies hepatic injury as unlikely at therapeutic doses, consistent with the broader GLP-1 receptor agonist class safety profile.

Mounjaro produces greater average weight loss than semaglutide — approximately 20–22% at maximum maintenance dose over 72 weeks in SURMOUNT trials. This magnitude of weight loss can produce transient liver enzyme elevations in the early months, particularly when weight loss exceeds 1.5kg per week during dose escalation.

The mechanism is identical to other GLP-1 medications: rapid fat mobilisation increases free fatty acid delivery to the liver. This is a physiological response, not drug-induced liver injury, and is self-limiting as weight loss pace stabilises.

Significant liver enzyme elevation — more than three times the upper limit of normal — occurs in less than 1% of patients on tirzepatide in clinical trials. Persistent elevations beyond 3 months warrant investigation for other causes.

Like all GLP-1 medications, Mounjaro is associated with increased gallstone risk. A systematic review of 76 studies found GLP-1 receptor agonists increase gallstone risk by 27% and gallbladder inflammation by 36%.

The highest risk period is the first 6–12 months when weight loss is most rapid — precisely when Mounjaro produces its greatest effect. Because the gallbladder shares the biliary tree with the liver, gallstone-related bile duct obstruction can produce liver enzyme elevations that may be misattributed to MASLD progression.

Watch for: right upper abdominal pain after eating, nausea, pain radiating to the right shoulder blade. Severe persistent pain with fever or jaundice requires urgent medical review.

Trials up to 84 weeks show consistent liver benefit — reduced liver fat, improved enzymes, and MASH resolution in dedicated liver disease studies. Beyond 84 weeks, very long-term hepatic outcome data for tirzepatide specifically does not yet exist.

The SYNERGY-NASH phase 3 trial — dedicated to Mounjaro's efficacy specifically for MASH — completed enrolment in 2025 with results expected in 2026. These will provide the most definitive long-term liver data for tirzepatide.

If Mounjaro is stopped and weight is regained, liver fat and enzyme levels are likely to worsen. The liver benefit is sustained by continued treatment and associated weight loss — not a permanent cure.

Mounjaro carries a boxed warning about thyroid C-cell tumours, based on rodent studies with tirzepatide. It is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome. This is not liver-related but is part of the complete safety picture.

Both medications share a similar side effect profile dominated by GI symptoms. Mounjaro may produce more intense early GI effects due to greater potency and faster weight loss. Liver safety profiles are broadly comparable — both show favourable hepatic outcomes with no significant hepatotoxicity in trials.

Mounjaro produces greater average weight loss (approximately 20% vs 14% for semaglutide at 72 weeks in head-to-head data), which may translate to greater liver fat reduction on average — but definitive head-to-head liver histology comparison data does not yet exist.

For patients on Mounjaro:

Before starting: Full liver function panel, FIB-4 calculation. Liver elastography if FIB-4 is indeterminate.

At 3 months: Repeat ALT/AST to assess early enzyme changes.

At 12 months: Repeat full liver function panel and FIB-4. Consider repeat elastography to assess response.

Annually thereafter: Liver function panel. Elastography every 1–2 years for patients with known MASLD or MASH.

Find a liver elastography clinic near you →